Shorter steroid course for severe PCP? new trial aims to find out
NCT ID NCT07328984
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how long steroids should be given to adults with severe Pneumocystis pneumonia (PCP), a serious lung infection common in people with weakened immune systems. About 416 participants who improve within 10 days will either stop steroids early or continue for 21 days. The goal is to see if stopping sooner reduces side effects like infections or diabetes without harming recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- systemic corticosteroids
- What this could lead to
- If successful, this could show that a shorter course of steroids is safer and just as effective for severe PCP, potentially changing standard treatment guidelines.
- What could go wrong
- This is a Phase 4 trial, so the drugs are already approved, but the optimal duration is unknown. The results may not apply to all patient groups, and earlier steroid stopping could increase the risk of relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCYSTIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital
Montreal, Quebec, H4A 3J1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New score could help doctors spot fungal pneumonia faster
- Could a simple swab replace a lung scope for pneumocystis diagnosis?
- Could a shorter steroid course be just as good for HIV-Related pneumonia?
- Could a lower dose of antibiotics be safer and just as effective for this lung infection?
- New drug could shield transplant patients from deadly fungal infections
- New study seeks best backup plan for deadly pneumonia in immunocompromised patients